TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16552540

Group type: EXPERIMENTAL
Intervention: Topical Licochalcone A (LicA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study: 12940503

Group type: EXPERIMENTAL
Intervention: D-cycloserine (0-500 mg/70 kg, per os)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: D-cycloserine (0-500 mg/70 kg, per os) combined with naloxone (0.15 mg/70 kg, intramuscularly)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Naloxone (0.15 mg/70 kg, intramuscularly)
Number of subjects: 6
Study: 10617748

Group type: EXPERIMENTAL
Intervention: DTaP vaccine
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: DTaP vaccines
Number of subjects: 327
Study: 9020562

Group type: EXPERIMENTAL
Intervention: beta‐2‐microglobulin concentration in serum
Number of subjects: 50

Group type: COMPARATOR
Intervention: beta‐2‐microglobulin concentration in urine
Number of subjects: 50

Group type: COMPARATOR
Intervention: treatment
Number of subjects: 50
Study: 1549149

Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate (10 mg/m²)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Very-low-dose methotrexate (5 mg/m²)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 3983884

Group type: EXPERIMENTAL
Intervention: Theophylline (10 mg/ml)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Glycine theophyllinate (50 mg/ml)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Aminophylline (50 mg/ml)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Diprophylline (125 mg/ml)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Salbutamol (200 micrograms from a metered dose inhaler)
Number of subjects: 17
Study: 29765082

Group type: EXPERIMENTAL
Intervention: Next generation sequencing (NGS)
Number of subjects: 490

Group type: COMPARATOR
Intervention: Population based Sanger sequencing (PBSS)
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: sDRM presence
Number of subjects: 490
Study: 27497474

Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation (CS) program, twice weekly for eight weeks (EG; n=36)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Usual care (CG; n=35)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation (CS) program
Number of subjects: 71
Study: 24559642

Group type: EXPERIMENTAL
Intervention: Yearlong multicomponent home-based rehabilitation program
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 81
Study: 22971882

Group type: EXPERIMENTAL
Intervention: Powered exercise machines incorporating only concentric contractions for 12 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 53
Study: 21036491

Group type: EXPERIMENTAL
Intervention: TVT
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 149
Study: 18159575

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine 3 mg + morphine 50 microg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine 3 mg + morphine 100 microg
Number of subjects: 40
Study: 15863536

Group type: EXPERIMENTAL
Intervention: Intensive exercise
Number of subjects: 52

Group type: COMPARATOR
Intervention: Home exercise
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups (operated and nonoperated)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Operated women
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training adherence
Number of subjects: 52
Study: 15513449

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone sodium succinate (1 gram IV/day for 3 days) followed by oral prednisone (1 mg/kg/day for 11 days) with 4‐day taper (20 mg on day 1, 10 mg on days 2 and 4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon beta 1‐a (Avonex 30microg intramuscularly [IM] weekly, or Rebif 22 microg subcutaneously [SQ] weekly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral prednisone alone, without prior treatment with IV methylprednisolone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IV methylprednisolone treatment followed by oral prednisone
Number of subjects: 0
Study: 9537209

Group type: EXPERIMENTAL
Intervention: Diflunisal 500 mg perorally twice a day for 7 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dipyrone 500 mg perorally three times a day for 7 days
Number of subjects: 50
Study: 9398952

Group type: EXPERIMENTAL
Intervention: 2 mg physostigmine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 40
Study: 1760167

Group type: EXPERIMENTAL
Intervention: IM ranitidine 1 mg/kg (n = 15)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IM ranitidine 2 mg/kg (n = 15)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 40
Study: 6114900

Group type: EXPERIMENTAL
Intervention: Pirenzepine (0.15 mg/kg) plus ranitidine (0.6 mg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned but implied as control)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pirenzepine plus ranitidine
Number of subjects: 8
Study: 31127404

Group type: EXPERIMENTAL
Intervention: Modified Screw Retained Arch Bar (SRAB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional Erich's Arch Bar (CEAB)
Number of subjects: 20
Study: 27631316

Group type: EXPERIMENTAL
Intervention: Responsive Insertion Technology (RIT)
Number of subjects: 647

Group type: COMPARATOR
Intervention: Conventional variable stiffness colonoscopes
Number of subjects: 647
Study: 24098434

Group type: EXPERIMENTAL
Intervention: Older adults (≥ 50 years)
Number of subjects: 3316

Group type: COMPARATOR
Intervention: Younger adults (18-49 years)
Number of subjects: 3316
Study: 22339822

Group type: EXPERIMENTAL
Intervention: Bisphosphonates combined with chemotherapy
Number of subjects: 53
Study: 19208456

Group type: EXPERIMENTAL
Intervention: Tat vaccine (7.5microg, 15microg, or 30microg doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17595890

Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg ER (evening)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg ER (morning)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg ER (morning and evening)
Number of subjects: 26
Study: 15823775

Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% ophthalmic solution (opened group)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (sealed travoprost 0.004% ophthalmic solution)
Number of subjects: 31
Study: 11590531

Group type: EXPERIMENTAL
Intervention: Newer drugs in the NRTI class and nucleotide RT inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NNRTIs and PIs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug resistance testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenotypic assays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Virtual Phenotype
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance testing
Number of subjects: 0
Study: 9402459

Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8509233

Group type: EXPERIMENTAL
Intervention: Alfacalcidol (6 micrograms daily for 6 months)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Supportive care (control)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 23
Study: 3495194

Group type: EXPERIMENTAL
Intervention: Autotransfusion (immediate centrifugation of oxygenator content after termination of cardiopulmonary bypass)
Number of subjects: 292

Group type: COMPARATOR
Intervention: No autologous transfusion (control group)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Autotransfusion
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Haemonetics software
Number of subjects: 292
Study: 31728713

Group type: EXPERIMENTAL
Intervention: Patisiran 0.3 mg/kg intravenously once every 3 weeks for 18 months
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 29606543

Group type: EXPERIMENTAL
Intervention: ASP7991 [1 mg, 18.5 kBq (500 nCi)]
Number of subjects: 6
Study: 27859700

Group type: EXPERIMENTAL
Intervention: Single-session 4-step cognitive-behavioral intervention program
Number of subjects: 22
Study: 24469862

Group type: EXPERIMENTAL
Intervention: Therapeutic music video (TMV) intervention
Number of subjects: 113

Group type: COMPARATOR
Intervention: Low-dose control (audiobooks)
Number of subjects: 113
Study: 22360799

Group type: EXPERIMENTAL
Intervention: High blood level in the air trap
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low blood level in the air trap
Number of subjects: 20
Study: 20061355

Group type: EXPERIMENTAL
Intervention: Intralipid 20%
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 18322300

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 35
Study: 16003451

Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy (simvastatin) for primary prevention in individuals with TC level higher than 6.2 mmol/L
Number of subjects: 15194

Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy (simvastatin) for secondary prevention in individuals with TC level higher than 6.2 mmol/L
Number of subjects: 15194

Group type: EXPERIMENTAL
Intervention: Lipid-lowering treatment for all individuals with TC level higher than 6.2 mmol/L
Number of subjects: 15194

Group type: EXPERIMENTAL
Intervention: Lipid-lowering treatment for all individuals regardless of TC levels
Number of subjects: 15194
Study: 12204809

Group type: EXPERIMENTAL
Intervention: atorvastatin 20, 40, and 80 mg/day
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: simvastatin 20, 40, and 80 mg/day
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: pravastatin 20, 40, and 80 mg/day
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: lovastatin 20, 40, and 80 mg/day
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: fluvastatin 20, 40, and 80 mg/day
Number of subjects: 86
Study: 10575423

Group type: EXPERIMENTAL
Intervention: Screening mammography
Number of subjects: 1500
Study: 8631045

Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5-5.0 mg per day
Number of subjects: 33841
Study: 1671389

Group type: EXPERIMENTAL
Intervention: Met-GH infusion (80 ng/kg.min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 12
Study: 6134041

Group type: EXPERIMENTAL
Intervention: Nicotine-containing cigarettes
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Noradrenaline
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nicotine-free cigarettes
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nicotine-containing tobacco smoke
Number of subjects: 24
Study: 31759286

Group type: EXPERIMENTAL
Intervention: Active intervention (problem-based sessions with cognitive behavioural components)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Positive control (not specified)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Negative control (not specified)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Active intervention
Number of subjects: 214
Study: 30207423

Group type: EXPERIMENTAL
Intervention: Nutrition (N)
Number of subjects: 3652

Group type: EXPERIMENTAL
Intervention: Combined Water, Sanitation, and Handwashing + Nutrition (WSH + N)
Number of subjects: 3652

Group type: COMPARATOR
Intervention: Active control (C)
Number of subjects: 3652
Study: 29979711

Group type: EXPERIMENTAL
Intervention: Warmer months (temperature increase)
Number of subjects: 1219

Group type: EXPERIMENTAL
Intervention: Colder months (temperature increase)
Number of subjects: 1219

Group type: EXPERIMENTAL
Intervention: Increasing precipitation in warmer months
Number of subjects: 1219

Group type: EXPERIMENTAL
Intervention: Increasing precipitation in colder months
Number of subjects: 1219
Study: 27321488

Group type: EXPERIMENTAL
Intervention: Ulinastatin treatment (8×10^5 U, twice a day for 7 days)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ulinastatin treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 40
Study: 24786361

Group type: EXPERIMENTAL
Intervention: PTSD treatment
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Trauma‐potentiated startle response
Number of subjects: 17
Study: 22270199

Group type: EXPERIMENTAL
Intervention: Hydrogel vehicle
Number of subjects: 20

Group type: COMPARATOR
Intervention: Moisturizing lotion (Eucerin Lotion)
Number of subjects: 20
Study: 19497591

Group type: COMPARATOR
Intervention: BC
Number of subjects: 22

Group type: COMPARATOR
Intervention: BC + 5 mg propranolol
Number of subjects: 22

Group type: COMPARATOR
Intervention: BC + 10 mg propranolol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 22
Study: 17464583

Group type: EXPERIMENTAL
Intervention: Upright position during the first stage of labor
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (not informed about upright position)
Number of subjects: 107
Study: 15700851

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with vincristine (VCR), methotrexate (MTX), and doxorubicin (ADM)
Number of subjects: 106
Study: 12704264

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 2

Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 2

Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 2
Study: 9839767

Group type: EXPERIMENTAL
Intervention: Donepezil HCl (5 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 20
Study: 7915824

Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5 to 1.0 mg twice weekly)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Bromocriptine (2.5 to 5.0 mg twice daily)
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 459

Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 459
Study: 2521641

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 1102234

Group type: EXPERIMENTAL
Intervention: dl‐Fenfluramine hydrochloride (240 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: dl‐Fenfluramine hydrochloride (60, 120 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: d‐amphetamine sulfate (20, 40 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31977520

Group type: EXPERIMENTAL
Intervention: 24 mg dexamethasone
Number of subjects: 130

Group type: COMPARATOR
Intervention: 8 mg dexamethasone
Number of subjects: 130
Study: 31094440

Group type: COMPARATOR
Intervention: Skin cancer education (control)
Number of subjects: 1573

Group type: EXPERIMENTAL
Intervention: Education plus a sunscreen activity
Number of subjects: 1573

Group type: EXPERIMENTAL
Intervention: Behavior change worksheet (sun protection goal setting and planning)
Number of subjects: 1573

Group type: EXPERIMENTAL
Intervention: Personalized UV damage photograph
Number of subjects: 1573
Study: 28372558

Group type: EXPERIMENTAL
Intervention: Linoleic acid in serum cholesterol esters (CE) and phospholipids (PL)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Palmitic acid in serum cholesterol esters (CE)
Number of subjects: 287
Study: 26066641

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Acupuncture with Manual Stimulation (MA)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Acupuncture with Electrical and Manual Stimulation (EA)
Number of subjects: 303
Study: 23441754

Group type: EXPERIMENTAL
Intervention: Laparoendoscopic single-site pyeloplasty
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional laparoscopic pyeloplasty
Number of subjects: 39
Study: 21319380

Group type: EXPERIMENTAL
Intervention: Drop in canales sacralis
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Acupotomy dissolution
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Combination of canales sacralis drop with acupotomy dissolution
Number of subjects: 139
Study: 18632766

Group type: EXPERIMENTAL
Intervention: Simvastatin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 16531710

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with UFT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 14966601

Group type: EXPERIMENTAL
Intervention: Shen Yang
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 213
Study: 11045848

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (10^10 CFU) in enterocoated tablets twice a day for 6 months
Number of subjects: 4
Study: 8615097

Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg for 5 days
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Tenoxicam 40 mg for 5 days
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147

Group type: COMPARATOR
Intervention: Morphine on the day of operation and placebo for 4 days
Number of subjects: 147
Study: 1576061

Group type: EXPERIMENTAL
Intervention: Yoghurt
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 7

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 7
Study: 4009494

Group type: EXPERIMENTAL
Intervention: Intravenous nicotine (0.75, 1.5 and 3.0 mg/10‐sec infusion)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inhaled nicotine (0.4, 1.4 and 2.9 mg estimated yield)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (sham‐smoking)
Number of subjects: 8
Study: 30371791

Group type: EXPERIMENTAL
Intervention: BIM23B065 (1.5 mg)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: BIM23B065 (multiple doses)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: BIM23B065 (high dosages)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: BIM23B065 (multiple ascending doses)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: BIM23B065
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 30094984

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) stimulation of bilateral Hegu(LI 4) and Sanyinjiao(SP 6) for 25 min, combined with medication (mifepristone and misoprostol tablets)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication (mifepristone and misoprostol tablets)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) stimulation of bilateral Hegu(LI 4) and Sanyinjiao(SP 6)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 27268039

Group type: EXPERIMENTAL
Intervention: Intermittent theta-burst stimulation (iTBS) applied to the left premotor cortex
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 15
Study: 25295843

Group type: EXPERIMENTAL
Intervention: Perioscope™ (tactile detection plus Perioscope)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Tactile explorer (tactile detection alone)
Number of subjects: 26
Study: 22447240

Group type: EXPERIMENTAL
Intervention: Effortful swallow with infrahyoid motor electrical stimulation (experimental group, n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Effortful swallow with infrahyoid sensory electrical stimulation (control group, n = 10)
Number of subjects: 20
Study: 20061873

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy plus cognitive restructuring
Number of subjects: 54

Group type: COMPARATOR
Intervention: Prolonged exposure therapy
Number of subjects: 54
Study: 17345556

Group type: EXPERIMENTAL
Intervention: Idursulfase (0.5 mg/kg) administered weekly
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Idursulfase (0.5 mg/kg) administered fortnightly
Number of subjects: 96

Group type: COMPARATOR
Intervention: Idursulfase (0.5 mg/kg)
Number of subjects: 96
Study: 15857744

Group type: EXPERIMENTAL
Intervention: Modified Brief Pain Inventory (BPI-DPN)
Number of subjects: 255
Study: 12066729

Group type: EXPERIMENTAL
Intervention: ProSeal
Number of subjects: 180

Group type: COMPARATOR
Intervention: Classic laryngeal mask airway
Number of subjects: 180
Study: 9573910

Group type: EXPERIMENTAL
Intervention: Uncertainty management intervention
Number of subjects: 403
Study: 7706611

Group type: EXPERIMENTAL
Intervention: Corn oil (CO)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Beef tallow (BT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both fats (CO and BT)
Number of subjects: 12
Study: 2198233

Group type: COMPARATOR
Intervention: Propranolol alone (20-80 mg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Propranolol in combination with dilazep (50 mg three times a day)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combination of propranolol and dilazep
Number of subjects: 34
Study: 346219

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (high-dose methotrexate, adriamycin, and vincristine)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Transfer factor
Number of subjects: 32

Group type: COMPARATOR
Intervention: Combination chemotherapy
Number of subjects: 32
Study: 30829668

Group type: EXPERIMENTAL
Intervention: IV infusion of phenylephrine at 0.25 µg/kg/min
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: IV infusion of phenylephrine at 0.375 µg/kg/min
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: IV infusion of phenylephrine at 0.5 µg/kg/min
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: IV infusion of phenylephrine at 0.625 µg/kg/min
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Prophylactic phenylephrine infusion
Number of subjects: 80
Study: 31526276

Group type: EXPERIMENTAL
Intervention: FIFA 11+ injury prevention program
Number of subjects: 1825

Group type: COMPARATOR
Intervention: Usual warm-up routine (control)
Number of subjects: 1825
Study: 27987236

Group type: EXPERIMENTAL
Intervention: Naltrexone (100 mg orally)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 26444161

Group type: EXPERIMENTAL
Intervention: Foot reflexology (12 sessions)
Number of subjects: 45
Study: 23589806

Group type: EXPERIMENTAL
Intervention: Intervention schools
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 1050
Study: 21756566

Group type: EXPERIMENTAL
Intervention: Exercise treatment for shoulder pain (12-week at-home program)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 58
Study: 19250705

Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention
Number of subjects: 1493

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 1493